<DOC>
	<DOCNO>NCT00472290</DOCNO>
	<brief_summary>This open label extension study romiplostim treatment thrombocytopenia ( platelet count ≤ 50 x 10^9/L ) MDS subject . The study design ass long-term safety treatment romiplostim , measure incidence overall adverse event , incidence bleeding event , utilization platelet transfusion , duration platelet response . The study describe time disease progression acute myeloid leukemia ( AML ) survival .</brief_summary>
	<brief_title>Evaluating Safety Long Term Dosing Romiplostim ( Formerly AMG 531 ) Thrombocytopenic Subjects With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Inclusion Criteria Subject complete romiplostim study treatment thrombocytopenia subject MDS Subject Eastern Cooperative Oncology ( ECOG ) performance status 0 2 Subject platelet count ≤ 50 x 10^9/L since final dose investigational product parent study Subject his/her legally acceptable representative provide write informed consent studyspecific procedure initiate Exclusion Criteria Subject diagnose AML blast count ≥ 10 % peripheral blood bone marrow biopsy Subject prior history leukemia Subject prior history bone marrow stem cell transplantation Subject prior malignancy ( situ cervical cancer , control prostate cancer , basal cell cancer skin ) unless treat curative intent without evidence disease ≥ 3 year randomization Subject active uncontrolled infection Subject unstable angina , congestive heart failure [ New York Heart Association ( NYHA ) &gt; class II ] , uncontrolled hypertension ( diastolic &gt; 100 mmHg ) , uncontrolled cardiac arrhythmia , recent ( within 1 year ) myocardial infarction Subject history arterial thrombosis ( eg , stroke transient ischemic attack ) past year Subject history venous thrombosis currently require anticoagulation therapy Subject receive interleukin ( IL ) 11 within 4 week screen Subject previously receive thrombopoietic growth factor ( romiplostim ) Subject know hypersensitivity recombinant E coliderived product ( eg , Infergen® , Neupogen® , Somatropin , Actimmune ) Subject currently enrol investigational device drug study ( y ) , yet complete least 4 week since end investigational device drug study ( y ) ( parent romiplostim study ) , subject receive investigational agent ( ) /device ( ) Subject childbearing potential evidently pregnant ( eg , positive human chorionic gonadotropin [ HCG ] test ) breast feed Subject use adequate contraceptive precaution Subject kind disorder compromise his/her ability give write informed consent ( legally acceptable representative ) unable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Hematology</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>